HWM
ALNY icon

Hemington Wealth Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Hemington Wealth Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$40K Buy
88
+1
+1% +$407 0.01% 419
2025
Q2 		$28K Buy
87
+21
+32% +$5.81K ﹤0.01% 495
2025
Q1 		$17K Buy
66
+18
+38% +$4.63K ﹤0.01% 615
2024
Q4 		$11K Buy
48
+12
+33% +$3.16K ﹤0.01% 725
2024
Q3 		$9K Buy
+36
New +$9.37K ﹤0.01% 727

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Hemington Wealth Management's ALNY Position: Q3 2025 in Review

Hemington Wealth Management increased its Alnylam Pharmaceuticals (ALNY) stake by 1.1% in Q3 2025, buying an estimated $407 and bringing the position to 88 shares worth $40K. The position accounts for 0.01% of the portfolio, ranked #419.

Hemington Wealth Management first reported a position in ALNY in Q3 2024 and has held it in 5 quarters since. 823 funds tracked by Wall St. Rank hold ALNY as of Q3 2025.

  • Hemington Wealth Management held 88 shares of Alnylam Pharmaceuticals worth $40K as of Q3 2025.
  • Hemington Wealth Management bought 1 Alnylam Pharmaceuticals share in Q3 2025, an estimated $407.
  • Alnylam Pharmaceuticals made up 0.01% of Hemington Wealth Management's portfolio in Q3 2025, its #419 holding.
  • Hemington Wealth Management first reported a position in Alnylam Pharmaceuticals in Q3 2024 and has held it in 5 quarters since.
  • 823 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2025.

Based on Hemington Wealth Management's 13F filing for Q3 2025, filed 24 Oct 2025.